BriaCell Therapeutics BCTX Income Statement (2019-2026)

NASDAQ BCTX
$3.93 -0.02 (-0.51%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Aug2019 Jul2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026
Shares Outstanding (Entity) (Quarter)
0.03M0.10M0.11M0.10M0.10M0.10M0.10M0.10M0.11M0.11M0.11M0.11M0.12M0.18M0.29M0.37M0.42M1.88M2.80M7.25M
Operating items
Research & Development (Quarter)
0.58M0.88M1.71M2.27M3.17M3.26M3.05M3.86M5.17M6.86M8.26M7.66M4.41M3.67M5.68M4.81M7.11M6.68M6.05M5.97M
Selling, General & Administrative (Quarter)
1.02M1.41M1.94M1.85M2.07M2.15M1.43M1.82M2.54M1.65M1.57M1.57M1.36M1.49M1.48M1.52M1.44M1.64M1.48M1.65M
Rent Expense (Quarter)
0.01M0.03M0.03M
Other Operating Expenses (Quarter)
-0.01M-0.03M-0.03M
Operating Expenses (Quarter)
1.60M2.28M3.65M4.12M5.23M5.40M4.49M5.68M7.71M8.50M9.83M9.23M5.77M5.15M7.17M6.33M8.55M8.32M7.53M7.62M
Operating Income (Quarter)
-1.60M-2.28M-3.65M-4.12M-5.23M-5.40M-4.49M-5.68M-7.71M-8.50M-9.83M-9.23M-5.77M-5.15M-7.17M-6.33M-8.55M-8.32M-7.53M-7.62M
EBIT (Quarter)
-1.60M-2.28M-3.65M-4.12M-5.23M-5.40M-4.49M-5.68M-7.71M-8.50M-9.83M-9.23M-5.77M-5.15M-7.17M-6.33M-8.55M-8.32M-7.53M-7.62M
Non-operating items
Non Operating Investment Income (Quarter)
0.09M0.14M
Interest & Investment Income (Quarter)
0.01M0.01M0.04M0.08M0.19M0.24M0.25M0.21M0.19M0.08M0.02M2.000.01M0.05M0.03M0.03M0.05M0.11M0.22M
Other Non Operating Income (Quarter)
17.84M34.00-0.01M228.00-0.02M-0.01M-0.01M-0.01M-0.01M-0.01M33.00-0.00M-0.01M-0.00M0.02M585.00-0.04M0.02M-0.02M-0.00M
Non Operating Income (Quarter)
-25.25M14.81M-5.89M4.78M4.30M-7.40M0.78M3.17M0.18M0.08M0.01M-0.01M0.01M0.07M-0.01M0.05M0.16M0.08M0.19M
Net income details
EBT (Quarter)
-2.77M-2.28M-3.87M-4.84M-5.15M-5.32M-6.37M-7.49M-7.50M-8.35M-9.75M-9.21M-5.77M-5.18M-7.12M-6.34M-8.48M-8.32M-7.43M-7.43M
Profit After Tax (Quarter)
-2.72M-27.53M11.16M-10.02M-0.45M-1.11M-11.88M-4.90M-2.42M-8.28M-11.33M1.72M-1.25M-5.83M-6.34M-6.22M-8.16M-8.28M-7.30M-7.24M
Income from Non-Controlling Interests (Quarter)
-0.04M-0.04M-0.02M-0.03M-0.03M-0.05M-0.10M-0.07M-0.08M-0.08M-0.07M
Income from Continuing Operations (Quarter)
-2.77M-2.28M-3.87M-4.84M-5.15M-5.32M-6.37M-7.49M-7.50M-8.35M-9.75M-9.21M-5.77M-5.18M-7.12M-6.34M-8.48M-8.32M-7.43M-7.43M
Consolidated Net Income (Quarter)
-2.77M-2.28M-3.87M-4.84M-5.15M-5.32M-6.37M-7.49M-7.50M-8.35M-9.75M-9.21M-5.77M-5.18M-7.12M-6.34M-8.48M-8.32M-7.43M-7.43M
Income towards Parent Company (Quarter)
-2.77M-2.28M-3.87M-4.84M-5.15M-5.32M-6.37M-7.49M-7.50M-8.35M-9.75M-9.21M-5.77M-5.18M-7.12M-6.34M-8.48M-8.32M-7.43M-7.43M
Net Income towards Common Stockholders (Quarter)
-2.77M-27.53M-3.87M-4.84M-5.15M-1.11M-6.37M-4.90M-11.88M6.00M-9.75M1.72M-11.29M-5.80M-7.12M-6.34M-8.48M-8.32M-7.43M-7.43M
Additional items
EPS (Basic) (Quarter)
-92.06-271.01-36.72-47.26-49.87-10.70-61.54-47.32-114.1056.33-91.4916.10-102.95-32.67-26.38-16.97-20.05-4.42-2.65-1.02
EPS (Diluted) (Quarter)
-92.06-913.76-31.50-47.26-49.87-10.70-61.54-47.32-114.1053.98-91.4916.10-102.95-32.67-26.38-16.97-20.05-4.42-2.65-1.02
Shares Outstanding (Quarter)
0.03M0.10M0.11M0.10M0.10M0.10M0.10M0.10M0.10M0.11M0.11M0.11M0.11M0.18M0.27M0.37M0.42M1.88M2.80M7.25M
Shares Outstanding (Diluted) (Quarter)
0.03M0.03M0.12M0.10M0.10M0.10M0.10M0.10M0.10M0.11M0.11M0.11M0.11M0.18M0.27M0.37M0.42M1.88M2.80M7.25M
EBITDA (Quarter)
-1.60M-2.28M-3.65M-4.12M-5.23M-5.40M-4.49M-5.68M-7.71M-8.50M-9.83M-9.23M-5.77M-5.15M-7.17M-6.33M-8.55M-8.32M-7.53M-7.62M
Interest Expenses (Quarter)
0.01M979.000.02M0.11M2.12M2.06M500.000.04M0.00M0.04M0.04M-0.04M0.04M500.000.03M